Drug Metabolism and Pharmacokinetics最新文献_第7页

Why and when do i use PBPK modeling 为什么以及何时使用PBPK建模

IF 2.7 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2025-06-01 DOI: 10.1016/j.dmpk.2025.101060

Kunal Taskar

引用次数: 0

Oligonucleotide target engagement 寡核苷酸目标交战

IF 2.7 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2025-06-01 DOI: 10.1016/j.dmpk.2025.101076

Michael McCoy

引用次数: 0

Alteration of blood brain-barrier proteome in various conditions 不同条件下血脑屏障蛋白质组的改变

IF 2.7 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2025-06-01 DOI: 10.1016/j.dmpk.2025.101113

Sumio Ohtsuki

引用次数: 0

The blood brain barrier demonstrates capability to influence heterogenous tenofovir and emtricitabine metabolism and transport in the brain 血脑屏障显示有能力影响异质替诺福韦和恩曲他滨在大脑中的代谢和运输

IF 2.7 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2025-06-01 DOI: 10.1016/j.dmpk.2025.101119

Hannah Wilkins , Ben Orsburn , Dionna Williams

引用次数: 0

Species specificity and selection of animal models for drug oxygenations differently contributed by polymorphic human enzymes 多态酶对药物氧合作用的物种特异性和动物模型的选择

IF 2.7 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2025-06-01 DOI: 10.1016/j.dmpk.2025.101105

Hiroshi Yamazaki

引用次数: 0

Drug-drug interaction between trastuzumab emtansine (T-DM1) and orally administered tacrolimus in a patient and in rats 曲妥珠单抗emtansine （T-DM1）和口服他克莫司在患者和大鼠中的药物相互作用

IF 2.7 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2025-06-01 DOI: 10.1016/j.dmpk.2025.101486

Tomohiro Nakamura , Moeko Shimada , Makiko Takabayashi , Arimi Fujita , Takahiro Kawakami , Hiroyuki Maruyama , Hirofumi Terakawa , Takahiro Ishimoto , Tsutomu Shimada , Toshihiro Miyamoto , Yoshimichi Sai

{"title":"Drug-drug interaction between trastuzumab emtansine (T-DM1) and orally administered tacrolimus in a patient and in rats","authors":"Tomohiro Nakamura , Moeko Shimada , Makiko Takabayashi , Arimi Fujita , Takahiro Kawakami , Hiroyuki Maruyama , Hirofumi Terakawa , Takahiro Ishimoto , Tsutomu Shimada , Toshihiro Miyamoto , Yoshimichi Sai","doi":"10.1016/j.dmpk.2025.101486","DOIUrl":"10.1016/j.dmpk.2025.101486","url":null,"abstract":"<div><div>We have experienced a 2.3-fold increase in the trough concentration of orally administered tacrolimus in a patient for 7 days after intravenous administration of trastuzumab emtansine (T-DM1), an antibody-drug conjugate. Retrospective clinical study revealed no change in factors known to alter the pharmacokinetics of tacrolimus, and the change in the trough concentration of tacrolimus was reversed after switching T-DM1 to trastuzumab (Tmab). Thus, interaction with T-DM1 was suspected as the cause of the increased trough concentration of tacrolimus. An animal study in rats showed that T-DM1 significantly increased the <em>AUC</em><sub>0-∞</sub> of orally administered tacrolimus by more than 2-fold on day 0, day 3, and day 7, whereas no change was observed in the case of intravenous administration of tacrolimus. T-DM1 also significantly increased <em>F</em><sub>a</sub>・<em>F</em><sub>g</sub> of tacrolimus by more than 2-fold on day 7. In contrast, Tmab itself had no effect on the blood concentration of tacrolimus. These results suggest that T-DM1 increased the blood concentration of orally administered tacrolimus, and the effect persisted for 1 week after T-DM1 administration. Metabolites of T-DM1 excreted via the biliary route may contribute to the increase in the gastrointestinal absorption of tacrolimus.</div></div>","PeriodicalId":11298,"journal":{"name":"Drug Metabolism and Pharmacokinetics","volume":"62 ","pages":"Article 101486"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144262469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Review of finalized ICH M12 guideline on drug interaction studies 对ICH M12药物相互作用研究指南定稿的审查

IF 2.7 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2025-06-01 DOI: 10.1016/j.dmpk.2025.101079

Akihiro Ishiguro

引用次数: 0

Driving compound optimization in early discovery by implementing mechanistic pharmacokinetic and machine learning models 通过实施机制药代动力学和机器学习模型，在早期发现中驱动化合物优化

IF 2.7 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2025-06-01 DOI: 10.1016/j.dmpk.2025.101090

Wenyi Wang

引用次数: 0

Development of dissolution evaluation system for drug absorption (V): Additional intestinal absorption module of in vitro 3D gastric emptying mmodel for orally disintegrating tablet 药物吸收溶出度评价系统的开发(V)：口腔崩解片体外三维胃排空模型的附加肠吸收模块

IF 2.7 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2025-06-01 DOI: 10.1016/j.dmpk.2025.101140

Kozo Tagawa , Akiko Kiriyama , San Yuet Lin , Sota Fukunaga

引用次数: 0

A tale of preclinical insights into bile salt homeostasis disruption in DILI DILI患者胆盐稳态紊乱的临床前研究

IF 2.7 4区医学

Drug Metabolism and Pharmacokinetics Pub Date : 2025-06-01 DOI: 10.1016/j.dmpk.2025.101108

Yurong Lai

引用次数: 0